Bionomics Limited (NASDAQ:BNOX) Sees Significant Increase in Short Interest

Bionomics Limited (NASDAQ:BNOX) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 190,300 shares, a growth of 1,279.0% from the October 15th total of 13,800 shares. Based on an average daily volume of 9,160,000 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC purchased a new stake in shares of Bionomics Limited (NASDAQ:BNOX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned about 15.03% of Bionomics as of its most recent SEC filing. Institutional investors and hedge funds own 15.90% of the company’s stock.

Bionomics Stock Performance

Shares of BNOX opened at $0.29 on Thursday. Bionomics has a fifty-two week low of $0.18 and a fifty-two week high of $2.19. The firm has a 50 day moving average price of $0.41 and a 200-day moving average price of $0.64.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Bionomics in a report on Thursday, August 1st.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.